阿加曲班联合依达拉奉治疗房颤合并脑栓塞的临床疗效评价

Efficacy Evaluation of Argatroban Combined with Edaravone in the Treatment of Cerebral Embolism Complicating with Atrial Fibrillation

目的:评价阿加曲班联合依达拉奉对房颤合并脑栓塞患者神经功能障碍治疗的有效性和安全性。方法:120例房颤合并脑栓塞患者随机分为2组,试验组给予阿加曲班联合依达拉奉治疗,对照组给予低分子肝素治疗,治疗前、后分别检测凝血功能,使用美国国立卫生院神经功能缺损评分(NIHSS评分)比较2组神经功能障碍程度,使用日常生活活动能力量表(Barthel指数)评价康复情况,统计临床治疗有效率,对结果进行统计分析。结果:2组治疗前凝血指标和NIHSS评分比较差异无统计学意义(P>0.05),治疗后试验组较对照组NIHSS评分有显著改善(P<0.05),试验组较对照组凝血时间延长(P<0.05);试验组与对照组有效率分别为91.38%、70.17%(P<0.01),出血事件发生率分别为3.33%、5.00%(P>0.05)。结论:早期使用抗凝药阿加曲班联合依达拉奉治疗房颤合并脑栓塞,疗效较好。

OBJECTIVE： To evaluate the effectiveness and safety of argatroban combined with edaravone in the treatment of neurological deficits in patients with cerebral embolism complicating with atrial fibrillation. METHODS： 120 patients with cerebral embolism complicating with atrial fibrillation were randomly divided into two groups. Trial group was treated with agatroban combined with edaravone and control group was treated with low molecular heparin. The coagulative functions of two groups were determined before and after treatment. The degrees of neurological deficits were compared between two groups using NIHSS scoring and the rehabilitation condition was evaluated by Barthel index. The effectiveness of clinical treatment was analyzed statistically. RESULTS： There were no significant difference in coagulation index and NIHSS scoring between two groups before treatment （P0.05）. The NIHSS scoring of trial group was improved significantly, compared with control group （P0.05）. The coagulation time of trial group was prolonged, compared with control group （P0.05）. The effective rates of trial group and control group were 91.38% and 70.17% （P0.01）. The incidence rates of bleeding were 3.33% and 5.00% （P0.05）. CONCLUSION： Early treatment of argatroban combined with edaravone is effective in the treatment of cerebral embolism complicating with atrial fibrillation.